Deutsche Bank AG Takes Position in Biohaven Ltd. $BHVN

Key Points

• Deutsche Bank AG acquired 201,499 Biohaven shares during the second quarter, worth approximately $3.0 million and representing about 0.13% of the company.
• Several institutional investors increased their positions, including AQR Capital, Mirae Asset, UBS Asset Management, Intech Investment Management and Quantbot Technologies; institutions collectively own 88.78% of Biohaven.
• Biohaven’s outlook received a boost from a potential $795 million licensing agreement with SK Biopharmaceuticals for its epilepsy platform, while investors await Phase 2/3 opakalim results expected in the second half of 2026. Analysts maintain a “Moderate Buy” consensus with an average price target of $18.94.

Deutsche Bank AG acquired a new stake in Biohaven Ltd. (NYSE:BHVN - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 201,499 shares of the company's stock, valued at approximately $2,998,000. Deutsche Bank AG owned approximately 0.13% of Biohaven at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. AQR Capital Management LLC lifted its stake in Biohaven by 49.4% during the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company's stock valued at $2,761,000 after acquiring an additional 37,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company's stock worth $1,747,000 after buying an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Biohaven by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company's stock valued at $14,174,000 after acquiring an additional 41,040 shares during the last quarter. Intech Investment Management LLC boosted its position in Biohaven by 80.3% in the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company's stock worth $1,481,000 after purchasing an additional 27,433 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Biohaven by 1,097.8% during the 2nd quarter. Quantbot Technologies LP now owns 8,840 shares of the company's stock valued at $125,000 after purchasing an additional 8,102 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company's stock.

Biohaven News Summary

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Major epilepsy licensing agreement: Biohaven licensed its Kv7 ion-channel platform, including lead epilepsy candidate opakalim, to SK Biopharmaceuticals in a deal potentially worth up to $795 million. The agreement includes upfront and milestone payments, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
• Positive Sentiment: Validation and potential funding: Opakalim is in Phase 2/3 development for focal epilepsy, and the partnership gives Biohaven a potential source of non-dilutive capital while adding a global development and commercialization partner. The deal also increased investor focus on the company’s broader pipeline. Biohaven and SK Biopharmaceuticals licensing announcement
• Positive Sentiment: Favorable trade-secret ruling: A federal court confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, formalizing a $4 million award to Biohaven and Yale University. The ruling removes uncertainty around the case and provides a financial recovery for Biohaven. Biohaven trade-secret lawsuit ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026. The licensing deal improves the commercial outlook, but milestone payments and royalties remain dependent on development, regulatory and sales outcomes. BHVN stock and upcoming trial readout

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BHVN shares. Needham & Company LLC set a $11.00 price objective on shares of Biohaven in a research report on Monday, June 29th. Royal Bank Of Canada raised their price target on Biohaven from $22.00 to $23.00 and gave the company an "outperform" rating in a report on Tuesday, August 11th. HC Wainwright restated a "neutral" rating and set a $10.00 target price on shares of Biohaven in a research report on Tuesday, May 26th. Raymond James Financial restated a "strong-buy" rating and set a $30.00 price target on shares of Biohaven in a report on Wednesday. Finally, TD Cowen restated a "buy" rating on shares of Biohaven in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $18.94.

Biohaven Stock Up 19.1%

Shares of Biohaven stock opened at $17.12 on Thursday. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -3.69 and a beta of 1.26. The firm's 50-day moving average is $14.74 and its two-hundred day moving average is $11.83.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.15). As a group, research analysts expect that Biohaven Ltd. will post -3.29 earnings per share for the current fiscal year.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source